

Press Release

Great Lakes Pharmaceuticals, Inc., Announces the Signing of Exclusive License Agreements with The University of Texas M. D. Anderson Cancer Center and Wake Forest University Health Sciences

Concord, Ohio, (February 21st, 2008) – Great Lakes Pharmaceuticals, Inc. announced today that it has entered into exclusive license agreements with The Board of Regents of The University of Texas System, acting on behalf of The University of Texas M. D. Anderson Cancer Center (“UTMDACC”), and Wake Forest University Health Sciences (“WFUHS”).

The Licenses grant Great Lakes Pharmaceuticals the exclusive worldwide rights to intellectual property owned jointly by The Board of Regents and WFUHS, and related intellectual property solely owned by the Board, to develop and commercialize certain antimicrobial catheter flush solutions.

Great Lakes Pharmaceuticals expects to leverage the licensed technology to bring to market a catheter flush solution with antimicrobial and antithrombotic properties designed to address the pressing problem of catheter-related bloodstream infections (“CRBSI”). Central venous catheters facilitate the administration of various therapeutic agents and collection of blood samples. The use of catheters, however, is often associated with infections and catheter occlusion. Centers for Disease Control and Prevention estimated annual occurrence of CRBSI cases at 250,000 with the cost to the healthcare system of approximately \$4.6 billion and with additional immeasurable suffering of the patients.

“Our goal is to leverage the licensed technologies to develop a product that completely eradicates microbial growth and biofilm formation in indwelling catheters and prevents catheter occlusion”, said Great Lakes Pharmaceutical’s President and CEO Krzysztof Appelt. “We expect our catheter flush solution, code named B-Lock™, to become a standard of care for hospital and outpatient applications greatly reducing the alarming rate of catheter-related bloodstream infections.”

B-Lock™ received a designation of "Combination Product with Device Primary Mode of Action" from the Office of Combination Products at the FDA. Such designation and assignment to the Center for Devices and Radiologic Health has traditionally led to a faster regulatory and commercialization timeline for a product as compared to a combination product designated as a "drug." Great Lakes Pharmaceuticals has entered into pre-IDE consultations with FDA and plans to initiate clinical trials in 2008.

About Great Lakes Pharmaceuticals, Inc.

Organized in Cleveland, Ohio in 2005, privately held Great Lakes Pharmaceuticals, Inc. is a development and commercialization company focused on products designed to eliminate microbial biofilm growth and prevent infections associated with indwelling venous catheters. Great Lakes Pharmaceuticals has experienced management team, and extensive R&D collaboration with the Case Western Reserve University and University Hospitals of Cleveland. The Company raised initial seed funding from the Case Technology Ventures and Cleveland-based JumpStart, Inc. To learn more about Great Lakes

Pharmaceuticals, Inc., please visit: www.glypharma.com.

About Wake Forest University Health Sciences

In 2002, the Wake Forest University Board of Trustees created Wake Forest University Health Sciences, as a wholly owned, nonprofit subsidiary. WFUHS operates the medical school, Piedmont Triad Research Park, and a number of other subsidiaries.

Wake Forest University School of Medicine and North Carolina Baptist Hospital together form Wake Forest University Baptist Medical Center. Programs of the medical school and hospital are interwoven to provide medical education, patient care, biomedical research, and community service of the highest professional level.

Contact Information:

Krzysztof Appelt

President and CEO

(760) 840-0572

e-mail: kappelt@glypharma.com